Onconetix Stock Price, News & Analysis

Onconetix, Inc. (Nasdaq: ONCO) is a commercial stage biotechnology company specializing in the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for oncology. Originally known as Blue Water Biotech, Inc. (BWV), the company underwent a transformation with its recent acquisition of Proteomedix AG, a commercial-stage diagnostics oncology firm from Switzerland. This strategic move reflects Onconetix's commitment to addressing significant unmet medical needs in the field of cancer treatment and diagnostics.

Products and Innovations:

• ENTADFI®: An FDA-approved, once-daily oral therapeutic for the treatment of benign prostatic hyperplasia (BPH). This treatment combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, offering a more effective solution compared to other available therapies. Clinical trials have shown that ENTADFI® is more effective in alleviating BPH symptoms with fewer adverse sexual side effects.
• Proclarix®: A CE-certified diagnostic tool for prostate cancer, available in Europe and expected to launch in the U.S. in 2024. It uses a risk score combining in-vitro assays and a proprietary algorithm to evaluate the risk of clinically significant prostate cancer based on specific biomarkers found in blood serum.

Strategic Shifts and Achievements:

Onconetix's rebranding and strategic acquisition of Proteomedix have positioned the company at the forefront of prostate cancer diagnostics and treatment. By integrating Proteomedix’s advanced diagnostic technologies, Onconetix aims to enhance its global footprint and solidify its commercial portfolio in oncology. Additionally, the company has shifted focus from its preclinical vaccine programs to concentrate on more targeted oncology initiatives.

Under the leadership of Dr. Neil J. Campbell, President and CEO, Onconetix continues to build key partnerships and acquire vital assets in the oncology space. This approach ensures the company’s commitment to delivering innovative solutions to clinicians, patients, and caregivers, while enhancing shareholder value.

For more information about Onconetix, Inc., visit www.onconetix.com.